Generalized pustular psoriasis
MONDO:0100491A rare and extreme form of psoriasis characterized by the appearance of sterile pustules which can take many patterns. All the main pathological features of the disease are accentuated. Generalized pustular psoriasis is clinically heterogeneous in its age at onset, precipitants, severity, and natural history. Many overlapping clinical entities are recognized. There is a relationship between these entities and plaque psoriasis, as some individuals may have episodes of plaque psoriasis preceding or following the generalized pustular psoriasis, but in others generalized pustular psoriasis occurs as the sole phenotype without plaque psoriasis at any time.
16 clinical trials for this condition and its sub-types.
Follow this condition — get notified about new trialsSub-types
Broader categories
-
New drug TAK-279 targets rare, severe psoriasis in phase 3 trial
Disease control CompletedThis phase 3 trial tests the drug TAK-279 in 18 adults with generalized pustular psoriasis or erythrodermic psoriasis, two rare and severe forms of the disease. All participants receive the drug for up to 52 weeks to see if it clears skin symptoms and is safe. The study is open-l…
Phase: PHASE3 • Sponsor: Takeda • Aim: Disease control
Last updated Aug 01, 2026 00:00 UTC
-
New drug shows promise for rare, severe psoriasis
Disease control CompletedThis Phase 3 trial tested a drug called imsidolimab in 45 adults with generalized pustular psoriasis (GPP), a rare and severe skin condition that causes painful pustules. Participants received either a single intravenous dose of imsidolimab (750 mg or 300 mg) or a placebo. The ma…
Phase: PHASE3 • Sponsor: Vanda Pharmaceuticals • Aim: Disease control
Last updated Jun 27, 2026 11:02 UTC
-
New drug spesolimab under Real-World watch for rare skin disease
Disease control CompletedThis study monitored 52 Japanese patients with generalized pustular psoriasis (GPP) who received spesolimab for acute symptoms. Researchers tracked side effects and disease activity in everyday clinical settings, not a controlled lab environment. The goal was to see how well the …
Sponsor: Boehringer Ingelheim • Aim: Disease control
Last updated Jun 27, 2026 07:55 UTC
-
New hope for rare skin Flare-Ups: drug offered to those with no options
Disease control CompletedThis program in China gave a single infusion of spesolimab to 39 people with a severe skin condition called generalized pustular psoriasis (GPP) during a flare-up. Participants had no other treatment options available. The goal was to control the flare and monitor for side effect…
Phase: PHASE3 • Sponsor: Boehringer Ingelheim • Aim: Disease control
Last updated Jun 27, 2026 07:55 UTC
-
New drug rapidly clears pustules in rare psoriasis flare
Disease control CompletedThis study tested a single dose of spesolimab in 53 people with generalized pustular psoriasis (GPP) experiencing a moderate-to-severe flare. The drug aims to quickly clear skin pustules. Results showed that more patients receiving spesolimab had no visible pustules after one wee…
Phase: PHASE2 • Sponsor: Boehringer Ingelheim • Aim: Disease control
Last updated Jun 27, 2026 07:54 UTC
-
Promising early results for rare psoriasis drug
Disease control CompletedThis study tested a drug called imsidolimab in 8 adults with generalized pustular psoriasis (GPP), a rare and severe skin condition. The drug is an antibody that targets inflammation. Researchers measured how well it worked using skin scores and other health markers. The goal was…
Phase: PHASE2 • Sponsor: Vanda Pharmaceuticals • Aim: Disease control
Last updated Jun 26, 2026 18:01 UTC
-
New shot could stop GPP flares before they start
Prevention CompletedThis study tested whether a monthly injection of spesolimab can prevent flare-ups of generalized pustular psoriasis (GPP), a rare and severe skin condition. 123 people aged 12 to 75 with clear or nearly clear skin joined the trial. They received either one of three doses of speso…
Phase: PHASE2 • Sponsor: Boehringer Ingelheim • Aim: Prevention
Last updated Jun 27, 2026 07:55 UTC
-
AI boosts doctor accuracy for rare skin diseases in new study
Knowledge-focused CompletedThis study tested whether an artificial intelligence (AI) tool could help doctors diagnose rare and tricky skin conditions like generalized pustular psoriasis (GPP). Fifteen doctors, including both general practitioners and dermatologists, looked at 100 skin images. They first ga…
Sponsor: AI Labs Group S.L • Aim: Knowledge-focused
Last updated Jun 27, 2026 09:07 UTC